Debye Analytics is developing a device that measures immune-specific markers directly at the point of collection, at the patient’s bedside.
Today, these markers are measured only in central laboratories. The cost and logistical effort involved means that, in practice, they are not measured at all in routine critical care. Our sensing technology removes the need for central lab processing, requires minimal manual input, and brings the cost down far enough for testing to become routine.
What makes this innovative is not a new biomarker, but the access it creates. For the first time, clinicians can see which immune subtype a patient has at the point of care, and can repeat the measurement as the illness progresses. That turns a one-off laboratory result into a live picture of how a patient’s immune system is responding: identifying deterioration earlier, and adapting treatment to the individual throughout their stay.
It also unlocks research that is currently impossible. Immune subtypes in sepsis and ARDS have so far been identified mainly by looking back at stored samples. Making these measurements routine and prospective is the step needed to develop treatment strategies matched to each subtype.